|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Arrhythmia, ventricular |
|
Fibrillation, atrial |
|
Flutter, atrial |
|
Tachycardia, ventricular |
| |
|
|
SIDE EFFECTS:
|
|
Cinchonism |
|
fever |
|
hepatitis |
|
hypotension |
|
syncope |
|
Blood dyscrasias, such as hemolytic anemia |
|
thrombocytopenia |
|
skin rash |
|
systemic lupus erythematosus-like condition |
|
Fatigue |
|
gastrointestinal symptoms, including anorexia |
|
diarrhea |
|
nausea |
|
vomiting |
|
muscle weakness |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> AV block, second-degree, without an artificial pacemaker |
|
>> Intraventricular conduction defects, severe, without an artificial pacemaker |
|
>> Sick sinus syndrome |
|
>> Bradycardia |
|
>> Electrolyte disorders , such as |
|
Hypocalcemia |
|
>> Hypokalemia |
|
Hypomagnesemia |
|
Congestive heart failure |
|
Hepatic function impairment |
|
Renal function impairment |
|
|
ADULT DOSE:
|
|
Atrial fibrillation or flutter (treatment)-
An optimal quinidine dosing regimen for the treatment of atrial fibrillation or flutter has not been established .
The following regimen has been used: Oral, 400 mg of quinidine sulfate every six hours .
If conversion to normal sinus rhythm does not occur after four or five doses, the dose may be carefully increased .
If at any point during administration the QRS complex widens to 130% of its pretreatment duration; the QTc interval widens to 130% of its pretreatment duration and is then longer than 500 milliseconds (ms); P waves disappear; or the patient develops significant tachycardia, symptomatic bradycardia, or hypotension, then quinidine should be discontinued, and other means of conversion, such as direct-current cardioversion, should be considered .
Atrial fibrillation or flutter (reduction of frequency of relapse)-
Oral, 200 mg of quinidine sulfate every six hours .
If the dose is well tolerated, quinidine serum concentrations are well within the therapeutic range, and the time between episodes has not been satisfactorily prolonged, the dose may be carefully increased .
If the QRS complex widens to 130% of its pretreatment duration; the QTc interval widens to 130% of its pretreatment duration and is then longer than 500 milliseconds (ms); P waves disappear; or the patient develops significant tachycardia, symptomatic bradycardia, or hypotension, the total daily dose should be reduced .
Ventricular arrhythmias-
Quinidine dosing regimens for the suppression of life-threatening ventricular arrhythmias have not been adequately studied .
Regimens that have been used are similar to the regimen for the reduction of frequency of relapse of atrial fibrillation or flutter stated above . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
[Atrial fibrillation or flutter or ventricular arrhythmias] -
Initial doses should be approximately 20 to 30 mg of quinidine sulfate per kg of body weight per day or 400 to 600 mg of quinidine sulfate per square meter of body surface area per day .
Doses of up to 60 mg of quinidine sulfate per kg of body weight per day or 1100 mg of quinidine sulfate per square meter of body surface area per day may be necessary in some children . |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|